Amphivena Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Amphivena Therapeutics's estimated annual revenue is currently $3.3M per year.
- Amphivena Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Amphivena Therapeutics has 21 Employees.
- Amphivena Therapeutics grew their employee count by -19% last year.
Amphivena Therapeutics's People
| Name | Title | Email/Phone |
|---|
Amphivena Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Amphivena Therapeutics?
Amphivena Therapeutics, Inc. is a privately held, clinical-stage, immuno-oncology company based in South San Francisco, CA that is developing a novel platform of dual-action biologics to selectively relieve immune suppression and drive T-cell activation/polarization, to restore anti-cancer immunity in patients. The company's lead therapeutic candidate, AMV564, induces selective T-cell mediated killing of myeloid derived suppressor cells (MDSC), known to be associated with immune suppression and poor outcomes to immunotherapy. In parallel, it drives improved T cell effector function. AMV564 has exhibited an excellent clinical safety profile and combinability with checkpoint inhibition and represents a unique opportunity to bring new treatment options to cancer patients under-served by immunotherapy.
keywords:N/A
N/A
Total Funding
21
Number of Employees
$3.3M
Revenue (est)
-19%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Amphivena Therapeutics News
NaNots are distinct from drug therapies in that they deplete soluble ... Dr. Ruegg served as CEO at Amphivena Therapeutics, developing new...
Other Companies in South San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.6M | 21 | -32% | $178.7M |
#2 | $1.7M | 22 | -80% | $187M |
#3 | $3.6M | 23 | 0% | N/A |
#4 | $3.6M | 23 | 5% | N/A |
#5 | $3.7M | 24 | 0% | N/A |